Taken together, our data provide evidence that NCL targeting inhibits the key hallmarks of malignancy in PCa cells and may provide a novel therapeutic option for patients with advanced-stage PCa. The gene discussed is NUCLEOLIN; the disease is posterior cortical atrophy.